Skip to main
RGEN
RGEN logo

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Repligen demonstrated strong financial performance in 4Q24, with total orders increasing by 11% both sequentially and year-over-year, and total orders for the full-year 2024 up by 9%. The company's revenue growth across all product segments, particularly in CDMO and capital equipment, highlights a robust momentum with sequential revenue increases of 20% and 30% respectively. Additionally, Repligen successfully expanded its adjusted gross margin by 140 basis points while maintaining disciplined cost control measures, indicating a solid foundation for continued profitability and growth.

Bears say

Repligen faces significant headwinds due to a slowdown in purchasing from small biotechs, which could lead to revenue declines within that sector. The company has downgraded its financial guidance twice, contributing to investor skepticism regarding its ability to provide conservative forward estimates amidst worsening visibility in customer inventory levels and spending plans. Additionally, concerns over potential delays in product launches, particularly related to technology shortages, and the transition of its long-standing CEO have introduced further uncertainty to Repligen's future performance.

Repligen (RGEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 20 analysts, Repligen (RGEN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $162.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $162.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.